BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)

SHA:688166 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	739.83	765.35	998.05	1,180	336.84	339.53
Trading Asset Securities	-	-	50.62	50.12	0.76	180.04
Cash & Short-Term Investments	739.83	765.35	1,049	1,230	337.6	519.58
Cash Growth	-22.46%	-27.02%	-14.78%	264.48%	-35.02%	-27.33%
Accounts Receivable	276.8	339.5	308.88	307.47	373.85	177.27
Other Receivables	7.67	6.66	19.91	18.78	3.75	0.92
Receivables	284.48	346.17	328.79	326.25	377.59	178.19
Inventory	372.42	364.61	344.63	280.35	200.06	203.2
Prepaid Expenses	-	-	3.65	5.83	4.48	5.76
Other Current Assets	147.2	164.14	114	95.39	73.27	39.64
Total Current Assets	1,544	1,640	1,840	1,938	993.01	946.36
Property, Plant & Equipment	2,716	2,705	2,489	2,076	1,378	452.5
Long-Term Investments	212.33	437.06	425.86	399.33	348.28	156.88
Goodwill	3.12	3.12	7.5	7.5	7.5	-
Other Intangible Assets	86.79	89.48	93.66	81.64	80.84	48.76
Long-Term Accounts Receivable	-	2.1	-	-	-	-
Long-Term Deferred Tax Assets	70.47	73.55	42.28	23.94	19.86	18.16
Long-Term Deferred Charges	264.36	57.49	30.18	26.87	25.83	33
Other Long-Term Assets	486.75	156.03	104.09	107.73	115.86	172.11
Total Assets	5,384	5,164	5,032	4,661	2,970	1,828
Accounts Payable	202.69	266	228.18	252.19	211.89	79.63
Accrued Expenses	24.02	75.5	72.31	69.04	61.72	37.47
Short-Term Debt	168.73	115.26	156.87	124.38	257.05	140.02
Current Portion of Long-Term Debt	-	516.96	397.93	313.87	16.58	2.56
Current Portion of Leases	-	13.69	16.1	1.34	9.87	-
Current Income Taxes Payable	-	16.68	14.04	14.97	3.69	5.44
Current Unearned Revenue	28.82	28.02	24	29.49	20.33	24.82
Other Current Liabilities	732.73	20.27	12.81	6.26	1.93	1.78
Total Current Liabilities	1,157	1,052	922.25	811.52	583.07	291.71
Long-Term Debt	1,495	1,580	1,615	1,576	618.69	77.52
Long-Term Leases	7.92	10.21	21.01	6.01	0.22	-
Long-Term Unearned Revenue	71.16	74.71	26.25	26	26	26
Other Long-Term Liabilities	67	10	29.82	-	-	-
Total Liabilities	2,798	2,727	2,614	2,420	1,228	395.23
Common Stock	422.77	422.47	422.47	422.47	410	410
Additional Paid-In Capital	1,095	982.36	1,057	1,008	738.94	701.01
Retained Earnings	1,029	1,046	897.66	743.35	555.05	345.54
Treasury Stock	-10.01	-10.01	-	-	-	-
Comprehensive Income & Other	-61.85	-46.48	-8.64	17.77	-25.8	-24.78
Total Common Equity	2,474	2,395	2,369	2,192	1,678	1,432
Minority Interest	111.85	42.73	48.97	50.04	63.45	0.78
Shareholders' Equity	2,586	2,437	2,418	2,242	1,742	1,433
Total Liabilities & Equity	5,384	5,164	5,032	4,661	2,970	1,828
Total Debt	1,671	2,236	2,207	2,022	902.42	220.1
Net Cash (Debt)	-931.37	-1,470	-1,158	-791.15	-564.82	299.48
Net Cash Growth	-	-	-	-	-	-58.11%
Net Cash Per Share	-2.21	-3.50	-2.75	-1.91	-1.39	0.72
Filing Date Shares Outstanding	426.67	422.11	422.1	422.47	410	410
Total Common Shares Outstanding	426.67	422.11	422.47	422.47	410	410
Working Capital	386.93	587.89	917.49	1,127	409.94	654.65
Book Value Per Share	5.80	5.67	5.61	5.19	4.09	3.49
Tangible Book Value	2,384	2,302	2,267	2,103	1,590	1,383
Tangible Book Value Per Share	5.59	5.45	5.37	4.98	3.88	3.37
Buildings	-	728.65	261.26	273.4	104.72	104.72
Machinery	-	1,122	704.8	318.41	287.37	253.45
Construction In Progress	-	1,167	1,736	1,666	1,131	219.14

Source: S&P Global Market Intelligence. Standard template. Financial Sources.